{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:23:12Z","timestamp":1783444992000,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajo.2026.04.028","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T15:14:46Z","timestamp":1777734886000},"page":"284-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unsuccessful Clinical Trials in Retina: Lessons Learned"],"prefix":"10.1016","volume":"288","author":[{"given":"Julie","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1772-3558","authenticated-orcid":false,"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2026.04.028_sbref0001","series-title":"FDA approves Syfovre (pegcetacoplan injection) for geographic atrophy secondary to AMD","year":"2023"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0002","series-title":"FDA approves Izervay (avacincaptad pegol) for geographic atrophy secondary to AMD","year":"2023"},{"key":"10.1016\/j.ajo.2026.04.028_bib0003","author":"Angela"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0004","series-title":"FDA approves Pavblu for retinal conditions","author":"Jeremias","year":"2024"},{"key":"10.1016\/j.ajo.2026.04.028_bib0005","author":"Mukamal"},{"key":"10.1016\/j.ajo.2026.04.028_bib0006","article-title":"diabetic eye disease: the therapeutic landscape","author":"Fowler","year":"2023","journal-title":"Retina Today"},{"key":"10.1016\/j.ajo.2026.04.028_bib0007","article-title":"Endpoints for clinical trials in ophthalmology","volume":"93","author":"Schmetterer","year":"2023","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1016\/j.ajo.2026.04.028_bib0008","first-page":"486","article-title":"Screen failures in clinical trials in retina","volume":"8","author":"Hasan","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"10.1016\/j.ajo.2026.04.028_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100213","article-title":"A clinical and preclinical assessment of clinical trials for dry age-related macular degeneration","volume":"2","author":"Abidi","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2026.04.028_bib0010","first-page":"26","article-title":"Overcoming retina clinical trial challenges with tailored solutions","year":"2023","journal-title":"Retin Physician"},{"key":"10.1016\/j.ajo.2026.04.028_bib0011","article-title":"FDA trials don\u2019t always reflect actual clinical settings","year":"2025","journal-title":"Rev Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.028_bib0012","first-page":"1","article-title":"Visualising treatment effects in low-vision settings: proven and potential endpoints for clinical trials of inherited retinal disease therapies","volume":"32","author":"Thirunavukarasu","year":"2025","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.028_bib0013","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/APO.0000000000000584","article-title":"Recent advances in clinical applications of imaging in retinal diseases","volume":"12","author":"Szeto","year":"2023","journal-title":"Asia-Pac J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.028_bib0014","author":"Vendor quality assurance audits: a formula for success: applied clinical trials online"},{"key":"10.1016\/j.ajo.2026.04.028_bib0015","author":"Discrepancies between clinician and reading center interpretations of OCT"},{"issue":"12","key":"10.1016\/j.ajo.2026.04.028_bib0016","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/s41433-022-02376-w","article-title":"A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices","volume":"37","author":"Michl","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.ajo.2026.04.028_bib0017","article-title":"Expanding access, enhancing research: the evolving landscape of ophthalmic clinical trials","author":"Vajzovic","year":"2025","journal-title":"Ophthalmol Times"},{"key":"10.1016\/j.ajo.2026.04.028_bib0018","article-title":"Opthea discontinues coast and ShORe trials in wet AMD","year":"2025","journal-title":"Ophthalmol Times"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.028_bib0019","first-page":"1","article-title":"Demystifying clinical trials and regulatory approvals in drug development (Edridge green lecture 2022)","volume":"39","author":"Chong","year":"2025","journal-title":"Eye (London)"},{"key":"10.1016\/j.ajo.2026.04.028_bib0061","article-title":"The complement pathway in geographic atrophy explained","author":"Alekseev","year":"2021","journal-title":"Retina Spec"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0062","series-title":"The complement system as a therapeutic target in retinal disease","author":"Ong","year":"2024"},{"issue":"6","key":"10.1016\/j.ajo.2026.04.028_bib0063","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/iovs.61.6.18","article-title":"Rare genetic variants in complement factor I lead to low fi plasma levels resulting in increased risk of age-related macular degeneration","volume":"61","author":"Hallam","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0020","series-title":"2000. Identifier NCT05697809, Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex\u00ae in the Treatment of Diabetic Macular Edema (OXEYE)","year":"2025"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0064","series-title":"Oxular doses first patients in OXEYE Phase 2 clinical trial of suprachoroidal OXU-001 as a long-acting treatment for diabetic macular edema","year":"2023"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0034","series-title":"Identifier NCT03446144, Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)","year":"2019"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0039","series-title":"Identifier NCT05893537, Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD)","year":"2025"},{"key":"10.1016\/j.ajo.2026.04.028_bib0047","author":"Silverwood"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0048","article-title":"OPTHEA parts with CEO, lays off over 80% of company","author":"Harp","year":"2025","journal-title":"Ophthalmol Times - Clin Insights Eye Spec"},{"key":"10.1016\/j.ajo.2026.04.028_bib0065","article-title":"Adverum slashes workforce by 38%, hones in on eye disease candidate","author":"Manalac","year":"2022","journal-title":"BioSpace"},{"key":"10.1016\/j.ajo.2026.04.028_bib0066","author":"Waldron"},{"key":"10.1016\/j.ajo.2026.04.028_bib0067","unstructured":"Fowler TE, Fromal OV, Jain N Diabetic eye disease: the therapeutic landscape. Bryn Mawr Commun; [Accessed October 23, 2025] https:\/\/retinatoday.com\/articles\/2023-nov-dec\/diabetic-eye-disease-the-therapeutic-landscape"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.028_bib0068","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/jop.2021.0001","article-title":"Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF Gene therapy for the treatment of neovascular AMD and diabetic macular edema","volume":"37","author":"Gelfman","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ajo.2026.04.028_bib0069","article-title":"Novartis to acquire gyroscope therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness","year":"2021","journal-title":"Novartis"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.028_bib0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.18240\/ijo.2022.01.23","article-title":"Progress of clinical therapies for dry age-related macular degeneration","volume":"15","author":"Rubner","year":"2022","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.028_bib0071","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/ICU.0000000000000948","article-title":"Novel oral medications for retinal disease: an update on clinical development","volume":"34","author":"DeBoer","year":"2023","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.028_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.943915","article-title":"Application and mechanism of anti-VEGF drugs in age-related macular degeneration","volume":"10","author":"Song","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.ajo.2026.04.028_bib0073","article-title":"Opthea\u2019s SOZINIBERCEPT Phase 2b clinical trial results in WET AMD","year":"2025","journal-title":"Opthea"},{"key":"10.1016\/j.ajo.2026.04.028_bib0074","author":"Opthea completes enrollment in pivotal phase 3 clinical program with sozinibercept in WET AMD"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0046","series-title":"Identifier NCT04757636, OPT-302 With Aflibercept in Neovascular Age-Related Macular Degeneration (nAMD) (COAST)","year":"2025"},{"key":"10.1016\/j.ajo.2026.04.028_sbref0049","series-title":"Identifier NCT04757610, OPT-302 With Aflibercept in Neovascular Age-Related Macular Degeneration (nAMD) (ShORe)","year":"2025"},{"key":"10.1016\/j.ajo.2026.04.028_bib0075","author":"Opthea Phase 2b trial results of OPT-302 in combination with Lucentis\u00ae for wet AMD published in the Journal Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2026.04.028_bib0076","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","article-title":"A randomized controlled trial of opt-302, a VEGF-C\/D inhibitor for neovascular age-related macular degeneration","volume":"130","author":"Jackson","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.04.028_bib0077","author":"Mahatole"},{"key":"10.1016\/j.ajo.2026.04.028_bib0078","article-title":"FDA issues complete response letter to outlook therapeutics for resubmitted BLA for ons-5010: ophthalmology times - clinical insights for eye specialists","author":"Harp","year":"2025","journal-title":"Ophthalmol Times - Clin Insights Eye Spec"},{"key":"10.1016\/j.ajo.2026.04.028_bib0079","author":"Outlook therapeutics provides regulatory update on U.S. Food and drug administration review of ONS-5010\/LytenavaTM (bevacizumab-vikg) for the treatment of WET AMD"},{"key":"10.1016\/j.ajo.2026.04.028_bib0052","unstructured":"ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT06190093, A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD). 2025 [Accessed September 03, 2025] https:\/\/clinicaltrials.gov\/study\/NCT06190093. National Library of Medicine (US). Identifier NCT03630952, Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2). 2021 [Accessed September 03, 2025] https:\/\/www.clinicaltrials.gov\/study\/NCT03630952"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:35:14Z","timestamp":1783442114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426002291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"alternative-id":["S0002939426002291"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.028","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unsuccessful Clinical Trials in Retina: Lessons Learned","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}